Escrever um comentário

Does the introduction explain the objective of the research presented in the preprint?

Yes

The introduction clearly explains the research objective by highlighting the challenges of converting unstructured pharmaceutical Batch Manufacturing Records (BMRs) into structured digital formats. It identifies limitations in existing document extraction methods and introduces an agentic AI workflow designed to transform BMR content into structured JSON while preserving document hierarchy, data integrity, and GMP compliance considerations. The objective is well defined and relevant to pharmaceutical digital transformation.

Are the methods well-suited for this research?

Somewhat appropriate

The methods are generally appropriate for the research objectives. The combination of OCR, vision-language models, structured JSON extraction, parallel processing, and multiple validation checks provides a practical approach to digitizing pharmaceutical batch manufacturing records. However, the evaluation is limited to three documents, which may not adequately represent the complexity and variability of real-world GxP documentation. Additional testing across diverse document types, along with clearer evidence of data integrity controls, traceability, and regulatory validation, would strengthen the reliability and applicability of the findings.

Are the conclusions supported by the data?

Somewhat supported

The conclusions are generally supported by the reported results, particularly regarding the feasibility of AI-assisted conversion of pharmaceutical batch manufacturing records into structured JSON. The findings demonstrate promising performance in preserving document hierarchy, calculations, and structural relationships. However, the evaluation is limited to three batch records, which restricts the generalizability of the conclusions. Additional evidence from larger and more diverse datasets, along with formal computerized system validation, data integrity assessments, and testing under production-representative GxP conditions, would strengthen the claims regarding scalability and regulatory compliance. Overall, the findings are encouraging, but some conclusions should be presented more cautiously.

Are the data presentations, including visualizations, well-suited to represent the data?

Somewhat appropriate and clear

The figures and tables are generally clear and appropriate for presenting the proposed workflow and its results. The examples showing the transformation of tables, calculations, and images into structured JSON help explain the technical approach. The performance metrics are also organized into useful categories, including structural integrity, content fidelity, and processing efficiency. However, additional comparative visualizations across the three evaluated batch records would make it easier to identify differences in extraction accuracy, document complexity, and processing performance. Clearer explanations of how the quality scores were calculated would further improve interpretation of the results.

How clearly do the authors discuss, explain, and interpret their findings and potential next steps for the research?

Somewhat clearly

The authors provide a clear discussion of their findings and explain the potential benefits of AI-assisted digitization of pharmaceutical Batch Manufacturing Records. They acknowledge important technical limitations, including handwriting recognition accuracy, document quality, and cross-chunk context preservation. The proposed future directions, such as enhanced GxP-specific training, multilingual capabilities, and collaborative review, are relevant and promising. However, the discussion could be strengthened by providing a more detailed roadmap for validating the system in regulated pharmaceutical environments, particularly regarding computerized system validation, audit trail integrity, change control, and ongoing performance monitoring. Overall, the findings and future research directions are presented clearly, with opportunities for greater emphasis on practical regulatory implementation.

Is the preprint likely to advance academic knowledge?

Somewhat likely

The preprint is likely to contribute to academic knowledge by demonstrating a practical approach to AI-assisted digitization of pharmaceutical Batch Manufacturing Records. The integration of vision-language models, structured JSON extraction, parallel processing, and pharmaceutical-specific validation checks provides useful insights into digital transformation in regulated manufacturing environments. However, the limited evaluation dataset and lack of comprehensive validation under production-representative GxP conditions restrict the broader applicability of the findings. Further research involving diverse manufacturing records, independent accuracy verification, and regulatory compliance assessments would strengthen the contribution.

Would it benefit from language editing?

No

The manuscript is generally well written, with clear explanations of the research objectives, technical methodology, and findings. Minor improvements in sentence structure, conciseness, and consistency of technical terminology would enhance readability. However, the language is sufficiently clear to understand the research, and extensive language editing does not appear necessary.

Would you recommend this preprint to others?

Yes, but it needs to be improved

I would recommend this preprint to researchers and professionals interested in AI-assisted pharmaceutical documentation and digital transformation. The proposed workflow offers a promising approach to converting Batch Manufacturing Records into structured digital formats while incorporating validation checks. However, the research would benefit from evaluation using a larger and more diverse dataset, stronger evidence of GxP compliance controls, and additional testing under production-representative conditions. These improvements would strengthen the reliability, generalizability, and practical applicability of the findings.

Is it ready for attention from an editor, publisher or broader audience?

Yes, after minor changes

The preprint is suitable for editorial consideration after revisions that clarify the scope and limitations of its findings. The proposed agentic AI workflow demonstrates promising results in converting pharmaceutical Batch Manufacturing Records into structured JSON. However, the authors should more clearly distinguish technical validation checks from formal GxP computerized system validation and avoid overstating production readiness. Additional discussion of data integrity, auditability, and human verification would strengthen the manuscript. The limited dataset should also be acknowledged when discussing scalability and generalizability.

Competing interests

The author declares that they have no competing interests.

Use of Artificial Intelligence (AI)

The author declares that they did not use generative AI to come up with new ideas for their review.